<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="216">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05158335</url>
  </required_header>
  <id_info>
    <org_study_id>MBX-2H1001</org_study_id>
    <nct_id>NCT05158335</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Single and Multiple Ascending Doses of MBX 2109 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MBX Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MBX Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and&#xD;
      pharmacodynamics of single and multiple doses of MBX 2109 in healthy volunteers.&#xD;
&#xD;
      This study includes 2 parts. Part A involves a single dose of MBX 2109 taken as a&#xD;
      subcutaneous (SC) injection just under the skin. Part B involves repeat doses of MBX 2109&#xD;
      taken as a SC injection just under the skin. Each participant will enroll in only one part.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2021</start_date>
  <completion_date type="Anticipated">February 3, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 16, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome Measures</measure>
    <time_frame>Baseline through Day 40 (part A) or Day 60 (Part B)</time_frame>
    <description>Number of participants with adverse events (AEs) or Serious Adverse Events (SAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Measures 1</measure>
    <time_frame>Baseline through Day 40 (part A) or Day 60 (Part B)</time_frame>
    <description>Pharmacokinetics (PK): Area Under the Concentration versus Time Curve (AUC) of MBX 2109</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Measures 2</measure>
    <time_frame>Baseline through Day 40 (part A) or Day 60 (Part B)</time_frame>
    <description>Pharmacodynamics (PD): change from baseline in albumin corrected serum calcium</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>MBX 2109 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending SC doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MBX 2109 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeated ascending SC doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX 2109 (Part A)</intervention_name>
    <description>Single ascending SC dose of MBX 2109: 50 µg, 150 µg, 240 µg, 360 µg, 440 µg, 540 µg</description>
    <arm_group_label>MBX 2109 (Part A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX 2109 (Part B)</intervention_name>
    <description>Repeated ascending SC doses of MBX 2109: 80 µg, 120 µg, 150 µg, 180 µg</description>
    <arm_group_label>MBX 2109 (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single SC dose or repeated SC doses of placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy men and women (of nonchildbearing potential) between 20 and 60 years of age,&#xD;
             inclusive.&#xD;
&#xD;
          2. Body mass index between 20.0 and 32.0 kg/m2, inclusive.&#xD;
&#xD;
          3. No clinically meaningful findings on physical examination, electrocardiogram,&#xD;
             laboratory tests or vital signs&#xD;
&#xD;
          4. Subject has been given signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of any significant illness or disorder&#xD;
&#xD;
          2. Acute illness within 30 days of administration of first dose of study drug&#xD;
&#xD;
          3. Positive screening result for HIV, hepatitis B or hepatitis C&#xD;
&#xD;
          4. History of or current substance abuse (drug or alcohol) within past 1 year or positive&#xD;
             test for drugs of abuse during screening&#xD;
&#xD;
          5. Use of nicotine-containing or vaping products within 3 months prior to screening or&#xD;
             check-in&#xD;
&#xD;
          6. Use of cannabis within 45 days prior to check-in&#xD;
&#xD;
          7. Donation of blood within 3 months prior to screening, plasma within 2 weeks prior to&#xD;
             screening or platelets within 6 weeks prior to screening&#xD;
&#xD;
          8. Participation in any other investigational study drug trial in which receipt of an&#xD;
             investigational study drug occurred within past 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Men and women of non-child bearing potential</gender_description>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Jane Geiger, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>MBX Biosciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Irene Mirkin, MD</last_name>
    <phone>(608) 442-8200</phone>
    <email>Irene.Mirkin@labcorp.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Labcorp Drug Development: Clinical Research Unit</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Lemons, RN, CRC</last_name>
      <phone>608-442-8200</phone>
      <email>Peter.Lemons2@Labcorp.com</email>
    </contact>
    <contact_backup>
      <last_name>Moua Thao</last_name>
      <phone>(608) 442-8200</phone>
      <email>Moua.Thao@Labcorp.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 2, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

